title: Drug target prediction and repositioning using an integrated network-based approach.
abstract: The discovery of novel drug targets is a significant challenge in drug development. Although the human genome comprises approximately 30,000 genes, proteins encoded by fewer than 400 are used as drug targets in the treatment of diseases. Therefore, novel drug targets are extremely valuable as the source for first in class drugs. On the other hand, many of the currently known drug targets are functionally pleiotropic and involved in multiple pathologies. Several of them are exploited for treating multiple diseases, which highlights the need for methods to reliably reposition drug targets to new indications. Network-based methods have been successfully applied to prioritize novel disease-associated genes. In recent years, several such algorithms have been developed, some focusing on local network properties only, and others taking the complete network topology into account. Common to all approaches is the understanding that novel disease-associated candidates are in close overall proximity to known disease genes. However, the relevance of these methods to the prediction of novel drug targets has not yet been assessed. Here, we present a network-based approach for the prediction of drug targets for a given disease. The method allows both repositioning drug targets known for other diseases to the given disease and the prediction of unexploited drug targets which are not used for treatment of any disease. Our approach takes as input a disease gene expression signature and a high-quality interaction network and outputs a prioritized list of drug targets. We demonstrate the high performance of our method and highlight the usefulness of the predictions in three case studies. We present novel drug targets for scleroderma and different types of cancer with their underlying biological processes. Furthermore, we demonstrate the ability of our method to identify non-suspected repositioning candidates using diabetes type 1 as an example.
authors.affiliation: IP & Science, Thomson Reuters, Carlsbad, California, United States of America.
authors.forename: Dorothea
authors.initials: D
authors.lastname: Emig
authors.forename: Alexander
authors.initials: A
authors.lastname: Ivliev
authors.forename: Olga
authors.initials: O
authors.lastname: Pustovalova
authors.forename: Lee
authors.initials: L
authors.lastname: Lancashire
authors.forename: Svetlana
authors.initials: S
authors.lastname: Bureeva
authors.forename: Yuri
authors.initials: Y
authors.lastname: Nikolsky
authors.forename: Marina
authors.initials: M
authors.lastname: Bessarabova
mesh_terms: D000465:Algorithms; D016000:Cluster Analysis; D019295:Computational Biology / Q000379:methods*; D003198:Computer Simulation; D055808:Drug Discovery / Q000379:methods*; D058492:Drug Repositioning; D020869:Gene Expression Profiling; D053263:Gene Regulatory Networks; D006801:Humans; D058990:Molecular Targeted Therapy; D012372:ROC Curve; D015203:Reproducibility of Results